Pembrolizumab Clinical Trials

A listing of Pembrolizumab medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Pembrolizumab is approved drug for the treatment of NSCLC. It works with your immune system to help fight certain cancers. The study is split into two portions - dose escalation and randomization.

epidermal growth factor
drug test
small cell lung cancer
growth factor
metastatic nsclc
  • 0 views
  • 19 Feb, 2024
  • 39 locations
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

platinum-based chemotherapy
melanoma
hair thinning
solid tumor
vascular endothelial growth factor
  • 0 views
  • 19 Feb, 2024
  • 1 location
Longitudinal Immune-phenotyping of HCC Following MK-3475

The study comprises a main study of pembro-treated HCC patients and a sub-study of untreated HCC patients. In the main study, patients will be treated with pembrolizumab as neoadjuvant treatment approximately 4 weeks prior scheduled surgery. Adjuvant treatment with pembrolizumab with commence at approximately 4 weeks post-surgery for up to …

chronic infection
hepatectomy
radiofrequency ablation
hepatitis b core antibody
carcinoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

During the Combination Therapy Period, the safety and preliminary anti-tumor activity of selinexor in combination with docetaxel (for patients with NSCLC) or pembrolizumab (for patients with CRC) will be evaluated.

kras
metastatic nsclc
solid tumor
monoclonal antibody therapy
combination therapy
  • 0 views
  • 19 Feb, 2024
  • 3 locations
A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

advanced malignant solid tumor
measurable disease
metastasis
gene amplification
solid tumor
  • 0 views
  • 19 Feb, 2024
  • 7 locations
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

This pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival, overall survival) and safety (rates of adverse events, quality of life) when treating Performance Status 2 patients with the …

carboplatin/paclitaxel
small cell lung cancer
metastasis
cancer therapy
pembrolizumab
  • 0 views
  • 19 Feb, 2024
  • 1 location
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcome when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for …

platinum-based chemotherapy
metastatic non-small cell lung cancer
stage iv nsclc
ret inhibitor
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
  • 1 location
Development and Analysis of a Stool Bank for Cancer Patients

This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are …

cancer treatment
immunotherapies
pembrolizumab
cancer immunotherapy
  • 0 views
  • 19 Feb, 2024
  • 2 locations